Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 237

1.

Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients.

Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P, Carr RM, Binder M, Finke CM, Gangat N, Al-Kali A, Begna KH, Reichard KK, Ketterling RP, Al Ali NH, Vafaii P, Zhang L, Padron E, Talati C, Patnaik MM.

Leukemia. 2019 Sep 11. doi: 10.1038/s41375-019-0574-x. [Epub ahead of print] No abstract available.

PMID:
31511613
2.

Disentangling hippocampal and amygdala contribution to human anxiety-like behaviour.

Bach DR, Hoffmann M, Finke C, Hurlemann R, Ploner CJ.

J Neurosci. 2019 Sep 9. pii: 0412-19. doi: 10.1523/JNEUROSCI.0412-19.2019. [Epub ahead of print]

PMID:
31501296
3.

Computerized Cognitive Training in Multiple Sclerosis: A Systematic Review and Meta-analysis.

Lampit A, Heine J, Finke C, Barnett MH, Valenzuela M, Wolf A, Leung IHK, Hill NTM.

Neurorehabil Neural Repair. 2019 Sep;33(9):695-706. doi: 10.1177/1545968319860490. Epub 2019 Jul 22.

PMID:
31328637
4.

Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.

Coltro G, Lasho TL, Finke CM, Gangat N, Pardanani A, Tefferi A, Jevremovic D, Altman JK, Patnaik MM.

Am J Hematol. 2019 Jun 7. doi: 10.1002/ajh.25552. [Epub ahead of print] No abstract available.

PMID:
31173385
5.

Evaluation of the 3D fractal dimension as a marker of structural brain complexity in multiple-acquisition MRI.

Krohn S, Froeling M, Leemans A, Ostwald D, Villoslada P, Finke C, Esteban FJ.

Hum Brain Mapp. 2019 Aug 1;40(11):3299-3320. doi: 10.1002/hbm.24599. Epub 2019 May 15.

PMID:
31090254
6.

Standardization of T1w/T2w Ratio Improves Detection of Tissue Damage in Multiple Sclerosis.

Cooper G, Finke C, Chien C, Brandt AU, Asseyer S, Ruprecht K, Bellmann-Strobl J, Paul F, Scheel M.

Front Neurol. 2019 Apr 9;10:334. doi: 10.3389/fneur.2019.00334. eCollection 2019.

7.

Integrating across memory episodes: Developmental trends.

Shing YL, Finke C, Hoffmann M, Pajkert A, Heekeren HR, Ploner CJ.

PLoS One. 2019 Apr 22;14(4):e0215848. doi: 10.1371/journal.pone.0215848. eCollection 2019.

8.

Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.

Coston T, Pophali P, Vallapureddy R, Lasho TL, Finke CM, Ketterling RP, Carr R, Binder M, Mangaonkar AA, Gangat N, Al-Kali A, Litzow M, Zblewski D, Pardanani A, Tefferi A, Patnaik MM.

Am J Hematol. 2019 Jul;94(7):767-779. doi: 10.1002/ajh.25488. Epub 2019 May 3.

PMID:
30964202
9.

Childhood multiple sclerosis is associated with reduced brain volumes at first clinical presentation and brain growth failure.

Bartels F, Nobis K, Cooper G, Wendel E, Cleaveland R, Bajer-Kornek B, Blaschek A, Schimmel M, Blankenburg M, Baumann M, Karenfort M, Finke C, Rostásy K.

Mult Scler. 2019 Jun;25(7):927-936. doi: 10.1177/1352458519829698. Epub 2019 Apr 4.

PMID:
30945587
10.

Neuronal autoantibodies associated with cognitive impairment in melanoma patients.

Bartels F, Strönisch T, Farmer K, Rentzsch K, Kiecker F, Finke C.

Ann Oncol. 2019 May 1;30(5):823-829. doi: 10.1093/annonc/mdz083.

11.

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.

Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Begna KH, Elliott MA, Hook CC, Wolanskyj AP, Patnaik MM, Hanson CA, Ketterling RP, Sirhan S, Pardanani A, Gangat N, Busque L, Tefferi A.

Mayo Clin Proc. 2019 Apr;94(4):599-610. doi: 10.1016/j.mayocp.2018.08.022. Epub 2019 Feb 26.

PMID:
30824279
12.

Musical memory and hippocampus revisited: Evidence from a musical layperson with highly selective hippocampal damage.

Esfahani-Bayerl N, Finke C, Kopp U, Moon DU, Ploner CJ.

Cortex. 2019 Jan 29. pii: S0010-9452(19)30026-7. doi: 10.1016/j.cortex.2018.12.023. [Epub ahead of print]

PMID:
30795831
13.

A transdiagnostic pattern of psychiatric symptoms in autoimmune encephalitis.

Finke C.

Lancet Psychiatry. 2019 Mar;6(3):191-193. doi: 10.1016/S2215-0366(19)30038-0. Epub 2019 Feb 11. No abstract available.

14.

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model.

Vallapureddy RR, Mudireddy M, Penna D, Lasho TL, Finke CM, Hanson CA, Ketterling RP, Begna KH, Gangat N, Pardanani A, Tefferi A.

Blood Cancer J. 2019 Jan 25;9(2):12. doi: 10.1038/s41408-019-0175-y.

15.

A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy.

Gangat N, Phelps A, Lasho TL, Finke CM, Vallapureddy R, Hanson CA, Ketterling RP, Patnaik MM, Pardanani A, Tefferi A.

Blood Cancer J. 2019 Jan 24;9(2):11. doi: 10.1038/s41408-018-0167-3. No abstract available.

16.

Hippocampal Dentate Gyrus Atrophy Predicts Pattern Separation Impairment in Patients with LGI1 Encephalitis.

Hanert A, Rave J, Granert O, Ziegler M, Pedersen A, Born J, Finke C, Bartsch T.

Neuroscience. 2019 Feb 21;400:120-131. doi: 10.1016/j.neuroscience.2018.12.046. Epub 2019 Jan 6.

PMID:
30625332
17.

Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation.

Patnaik MM, Pophali PA, Lasho TL, Finke CM, Horna P, Ketterling RP, Gangat N, Mangaonkar AA, Pardanani A, Tefferi A.

Haematologica. 2019 Jun;104(6):e236-e239. doi: 10.3324/haematol.2018.208082. Epub 2019 Jan 3. No abstract available.

18.

20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients.

Penna D, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2019 Mar;94(3):286-290. doi: 10.1002/ajh.25351. Epub 2018 Dec 5.

PMID:
30516867
19.

The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis.

Tefferi A, Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Am J Hematol. 2019 Mar;94(3):299-305. doi: 10.1002/ajh.25349. Epub 2018 Dec 5.

PMID:
30516848
20.

MPL-mutated essential thrombocythemia: a morphologic reappraisal.

Szuber N, Hanson CA, Lasho TL, Finke C, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 20;8(12):121. doi: 10.1038/s41408-018-0159-3. No abstract available.

21.

Genetic predictors of response to specific drugs in primary myelofibrosis.

Penna D, Szuber N, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 19;8(12):120. doi: 10.1038/s41408-018-0158-4. No abstract available.

22.

Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates.

Szuber N, Lavu S, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 19;8(12):118. doi: 10.1038/s41408-018-0157-5. No abstract available.

23.

Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis.

Szuber N, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Leukemia. 2019 Mar;33(3):780-785. doi: 10.1038/s41375-018-0283-x. Epub 2018 Oct 12. No abstract available.

PMID:
30315236
24.

MRI Findings Suggestive of Herpes Simplex Encephalitis in Patients with Anti-NMDA Receptor Encephalitis.

Scheel M, Finke C.

AJNR Am J Neuroradiol. 2018 Nov;39(11):E120. doi: 10.3174/ajnr.A5788. Epub 2018 Sep 13. No abstract available.

PMID:
30213819
25.

Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms.

Patnaik MM, Lasho T, Howard M, Finke C, Ketterling RL, Al-Kali A, Pardanani A, Droin N, Gangat N, Tefferi A, Solary E.

Blood Cancer J. 2018 Aug 22;8(9):82. doi: 10.1038/s41408-018-0120-5. No abstract available.

26.

Anti-ARHGAP26 Autoantibodies Are Associated With Isolated Cognitive Impairment.

Bartels F, Prüss H, Finke C.

Front Neurol. 2018 Aug 10;9:656. doi: 10.3389/fneur.2018.00656. eCollection 2018.

27.

Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger.

Szuber N, Vallapureddy RR, Penna D, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2018 Dec;93(12):1474-1484. doi: 10.1002/ajh.25270. Epub 2018 Sep 27.

PMID:
30157297
28.

Mutations and karyotype predict treatment response in myelodysplastic syndromes.

Idossa D, Lasho TL, Finke CM, Ketterling RP, Patnaik MM, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2018 Nov;93(11):1420-1426. doi: 10.1002/ajh.25267. Epub 2018 Sep 30.

PMID:
30152885
29.

Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients.

Pophali P, Horna P, Lasho TL, Finke CM, Ketterling RP, Gangat N, Nagorney D, Tefferi A, Patnaik MM.

Am J Hematol. 2018 Nov;93(11):1347-1357. doi: 10.1002/ajh.25246. Epub 2018 Oct 5.

PMID:
30105755
30.

Selective vs stepwise removal of deep carious lesions in primary molars: 12-Months results of a randomized controlled pilot trial.

Elhennawy K, Finke C, Paris S, Reda S, Jost-Brinkmann PG, Schwendicke F.

J Dent. 2018 Oct;77:72-77. doi: 10.1016/j.jdent.2018.07.011. Epub 2018 Jul 17.

PMID:
30025748
31.

Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis.

Mudireddy M, Gangat N, Lasho TL, Finke C, Hanson CA, Ketterling RP, Ashrani AA, Pardanani A, Nagorney DM, Tefferi A.

Am J Hematol. 2018 Sep;93(9):E235-E238. doi: 10.1002/ajh.25203. Epub 2018 Aug 31. No abstract available.

32.

Beyond the limbic system: disruption and functional compensation of large-scale brain networks in patients with anti-LGI1 encephalitis.

Heine J, Prüss H, Kopp UA, Wegner F, Then Bergh F, Münte T, Wandinger KP, Paul F, Bartsch T, Finke C.

J Neurol Neurosurg Psychiatry. 2018 Nov;89(11):1191-1199. doi: 10.1136/jnnp-2017-317780. Epub 2018 Jun 9.

PMID:
29886429
33.

Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information.

Tefferi A, Gangat N, Mudireddy M, Lasho TL, Finke C, Begna KH, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, He R, Viswanatha D, Hanson CA, Ketterling RP, Tang JL, Chou WC, Lin CC, Tsai CH, Tien HF, Hou HA.

Mayo Clin Proc. 2018 Oct;93(10):1363-1374. doi: 10.1016/j.mayocp.2018.04.013. Epub 2018 Jun 14.

PMID:
29866419
34.

A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone.

Patnaik MM, Rangit Vallapureddy, Lasho TL, Hoversten KP, Finke CM, Ketterling RP, Hanson CA, Gangat N, Tefferi A, Pardanani A.

Leukemia. 2018 Aug;32(8):1850-1856. doi: 10.1038/s41375-018-0121-1. Epub 2018 Apr 2. No abstract available.

PMID:
29712989
35.

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.

Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Naseema Gangat, Pardanani A, Vannucchi AM.

Leukemia. 2018 Jul;32(7):1631-1642. doi: 10.1038/s41375-018-0107-z. Epub 2018 Mar 23.

36.

Diagnosing MRI-negative autoimmune diseases.

Finke C.

Neurol Neuroimmunol Neuroinflamm. 2018 Apr 2;5(3):e457. doi: 10.1212/NXI.0000000000000457. eCollection 2018 May. No abstract available.

37.

Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates.

Hoversten K, Vallapureddy R, Lasho T, Finke C, Ketterling R, Hanson C, Gangat N, Tefferi A, Patnaik MM.

Leuk Lymphoma. 2018 Dec;59(12):2998-3001. doi: 10.1080/10428194.2018.1452212. Epub 2018 Mar 27. No abstract available.

PMID:
29582697
38.

U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions.

Tefferi A, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Leukemia. 2018 Oct;32(10):2274-2278. doi: 10.1038/s41375-018-0078-0. Epub 2018 Feb 27. No abstract available.

39.

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms.

Lasho TL, Vallapureddy R, Finke CM, Mangaonkar A, Gangat N, Ketterling R, Tefferi A, Patnaik MM.

Blood Cancer J. 2018 Mar 12;8(3):32. doi: 10.1038/s41408-018-0057-8. No abstract available.

40.

U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates.

Tefferi A, Mudireddy M, Finke CM, Nicolosi M, Lasho TL, Hanson CA, Patnaik MM, Pardanani A, Gangat N.

Am J Hematol. 2018 Jun;93(6):E146-E148. doi: 10.1002/ajh.25084. Epub 2018 Apr 6. No abstract available.

41.

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.

Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Szuber N, Begna KH, Patnaik MM, Gangat N, Pardanani A, Tefferi A.

Blood Adv. 2018 Feb 27;2(4):370-380. doi: 10.1182/bloodadvances.2018015875.

42.

Multiple sclerosis-related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex.

Jaeger S, Paul F, Scheel M, Brandt A, Heine J, Pach D, Witt CM, Bellmann-Strobl J, Finke C.

Mult Scler. 2019 Apr;25(4):554-564. doi: 10.1177/1352458518758911. Epub 2018 Feb 21.

43.

CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival.

Szuber N, Finke CM, Lasho TL, Elliott MA, Hanson CA, Pardanani A, Tefferi A.

Blood Cancer J. 2018 Feb 15;8(2):21. doi: 10.1038/s41408-018-0058-7. No abstract available.

44.

Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts.

Mangaonkar AA, Lasho TL, Finke CM, Gangat N, Al-Kali A, Elliott MA, Begna KH, Alkhateeb H, Wolanskyj-Spinner AP, Hanson CA, Ketterling RP, Hogan WJ, Pardanani A, Litzow MR, Tefferi A, Patnaik MM.

Blood Cancer J. 2018 Feb 12;8(2):18. doi: 10.1038/s41408-018-0051-1. No abstract available.

45.

Mayo CALR mutation type classification guide using alpha helix propensity.

Lasho TL, Finke CM, Tischer A, Pardanani A, Tefferi A.

Am J Hematol. 2018 May;93(5):E128-E129. doi: 10.1002/ajh.25065. Epub 2018 Feb 24. No abstract available.

46.

Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model.

Gangat N, Mudireddy M, Lasho TL, Finke CM, Nicolosi M, Szuber N, Patnaik MM, Pardanani A, Hanson CA, Ketterling RP, Tefferi A.

Am J Hematol. 2018 May;93(5):691-697. doi: 10.1002/ajh.25064. Epub 2018 Feb 24.

47.

EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental.

Patnaik MM, Vallapureddy R, Lasho TL, Hoversten KP, Finke CM, Ketterling R, Hanson C, Gangat N, Tefferi A.

Blood Cancer J. 2018 Jan 22;8(1):12. doi: 10.1038/s41408-017-0045-4. No abstract available.

48.

Anatomical Wiring and Functional Networking Changes in the Visual System Following Optic Neuritis.

Backner Y, Kuchling J, Massarwa S, Oberwahrenbrock T, Finke C, Bellmann-Strobl J, Ruprecht K, Brandt AU, Zimmermann H, Raz N, Paul F, Levin N.

JAMA Neurol. 2018 Mar 1;75(3):287-295. doi: 10.1001/jamaneurol.2017.3880.

49.

Association of Visual Impairment in Neuromyelitis Optica Spectrum Disorder With Visual Network Reorganization.

Finke C, Zimmermann H, Pache F, Oertel FC, Chavarro VS, Kramarenko Y, Bellmann-Strobl J, Ruprecht K, Brandt AU, Paul F.

JAMA Neurol. 2018 Mar 1;75(3):296-303. doi: 10.1001/jamaneurol.2017.3890.

50.

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients.

Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2017 Dec 27;7(12):662. doi: 10.1038/s41408-017-0035-6.

Supplemental Content

Support Center